RT Journal Article
SR Electronic
T1 Using the Bayesian credible subgroups method to identify populations benefiting from treatment: An application to the Look AHEAD trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2019.12.10.19014357
DO 10.1101/2019.12.10.19014357
A1 Anna Coonan
A1 John Forbes
A1 Patrick Schnell
A1 Joel Smith
YR 2019
UL http://medrxiv.org/content/early/2019/12/14/2019.12.10.19014357.abstract
AB Traditionally, subgroup analyses are used to assess whether patient characteristics moderate treatment effectiveness with general disregard for issues of multiplicity. Using data from The Action for Health in Diabetes (Look AHEAD) trial in the United States, we aim to identify a subgroup where all of its types of members experience a treatment benefit defined as reducing the likelihood of a major cardiovascular event under an intensive lifestyle and weight-loss intervention. We apply the credible subgroups method to a Bayesian logistic model with a conservative prior that is sceptical of large treatment effect heterogeneity. The covariate profiles for which there is sufficient evidence of treatment benefit are, coarsely, middle-aged women, in poor subjective general health and with moderately to poorly controlled diabetes. There is at least 80% posterior probability that the conditional average treatment effect is positive for all covariate profiles fitting this description, which account for 0.5% of trial participants. Conversely, the covariate profiles that are likely to be associated with no benefit are middle aged and older men in excellent subjective general health, with well-controlled diabetes. These profiles apply to less than 2% of trial participants. More information is required to determine treatment benefit or no benefit for the remainder of the trial population.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT00017953Funding StatementThe work of AC and JF was funded by the Health Research Board (grant number HRB-RL-2013-11) The work of JS was funded by the National Institute for Health Research Biomedical Research Centre at the University of Oxford (grant number NIHR-BRC-1215-20008).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLegal requirements prohibit public sharing of the dataset. Data are available upon request from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). AC and JF had full access to all of the data and the final responsibility to submit for publication.